Evidence map›Paper›PMID 36512179›Full record

ArticleMolecular diagnosis & therapy2023

Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target.

Yura Son, Wuqiang Zhu

Abstract read
In one paragraph

Article in Molecular diagnosis & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Fundamental and Practical Perspectives in Regenerative Medicine.International journal of molecular sciences · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yura SonDepartment of Cardiovascular Diseases, Department of Physiology and Biomedical Engineering, and Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale, AZ, 85259, USA.
Wuqiang ZhuDepartment of Cardiovascular Diseases, Department of Physiology and Biomedical Engineering, and Center for Regenerative Medicine, Mayo Clinic Arizona, Scottsdale, AZ, 85259, USA. Zhu.Wuqiang@mayo.edu.ORCID http://orcid.org/0000-0001-5217-7789

Funding

Cardiomyocyte Non-autonomous Factors and Cardiac Regeneration in Large MammalsR01HL156855 · NHLBI · MAYO CLINIC ARIZONA · PI Wuqiang Zhu · 2022 to 2026
$3.3M
Strategies to Enhance Engineered Heart Tissue Based Myocardial RepairR01HL162747 · NHLBI · MAYO CLINIC ARIZONA · PI Jingwei Xie, Wuqiang Zhu · 2023 to 2026
$2.9M
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR01HL142627 · NHLBI · MAYO CLINIC ARIZONA · PI ZHU, WUQIANG · 2019 to 2022
$1.7M
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR56HL142627 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHU, WUQIANG · 2018 to 2018
$371k
National Institute of Health HL156855NHLBI NIH HHS R01 HL142627NHLBI NIH HHS R01 HL156855NHLBI NIH HHS R01 HL162747NHLBI NIH HHS R56 HL142627
6 · The paper itself

Abstract

Heart disease is the primary cause of death worldwide. Even though extensive research has been done, and many pharmacological and surgical treatments have been introduced to treat heart disease, the mortality rate still remains high. Gene therapy is widely used to understand molecular mechanisms of myocardial infarction and to treat cardiomyocyte loss. It was reported that adult cardiomyocytes proliferate at a very low rate; thus, targeting their proliferation has become a new regenerative therapeutic approach. Currently, re-activating cardiomyocyte proliferation appears to be one of the most promising methods to promote adult cardiomyocyte renewal. In this article, we highlight gene therapeutic targets of cell proliferation presently being pursued to re-activate the cell cycle of cardiomyocytes, including cell cycle regulators, transcription factors, microRNAs, signal transduction, and other contributing factors. We also summarize gene delivery vectors that have been used in cardiac research and major challenges to be overcome in the translation to the clinical approach and future directions.

Indexed as

Heart DiseasesMyocardial InfarctionCell CycleCell ProliferationGenetic TherapyHumansMyocytes, Cardiac

Identifiers

PMID36512179
PMCPMC10123801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.